$87.2 Million is the total value of M28 Capital Management LP's 11 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| WVE | Sell | WAVE LIFE SCIENCES LTD | $40,505,875 | +57.8% | 7,044,500 | -0.1% | 46.45% | +37.0% |
| INVIVYD INC | $15,722,025 | +61.9% | 9,248,250 | 0.0% | 18.03% | +40.5% | ||
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $10,722,007 | -14.4% | 523,280 | -17.0% | 12.30% | -25.7% |
| SWTX | SPRINGWORKS THERAPEUTICS INC | $4,570,824 | -11.8% | 197,700 | 0.0% | 5.24% | -23.5% | |
| SLN | SILENCE THERAPEUTICS PLCads | $3,572,516 | +78.5% | 363,800 | 0.0% | 4.10% | +55.0% | |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $3,196,044 | +11.8% | 121,200 | -27.1% | 3.66% | -3.0% |
| New | CURIS INC | $2,780,657 | – | 421,951 | +100.0% | 3.19% | – | |
| PRQR | PROQR THRAPEUTICS N V | $2,483,780 | -19.8% | 1,910,600 | 0.0% | 2.85% | -30.4% | |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | $1,811,038 | -24.6% | 67,400 | 0.0% | 2.08% | -34.6% | |
| TGTX | Buy | TG THERAPEUTICS INC | $1,810,776 | -48.8% | 216,600 | +52.0% | 2.08% | -55.6% |
| NEXI | NEXIMMUNE INC | $28,009 | -25.5% | 133,442 | 0.0% | 0.03% | -36.0% | |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -346,190 | -100.0% | -4.86% | – |
| CRIS | Exit | CURIS INC | $0 | – | -6,000,000 | -100.0% | -6.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 46.4% |
| INVIVYD INC | 8 | Q3 2023 | 32.1% |
| ROCKET PHARMACEUTICALS INC | 8 | Q3 2023 | 16.6% |
| BRIDGEBIO PHARMA INC | 8 | Q3 2023 | 6.1% |
| TG THERAPEUTICS INC | 8 | Q3 2023 | 9.2% |
| NEXIMMUNE INC | 8 | Q3 2023 | 0.5% |
| STOKE THERAPEUTICS INC | 7 | Q2 2023 | 10.2% |
| CURIS INC | 7 | Q2 2023 | 9.7% |
| PROQR THRAPEUTICS N V | 7 | Q3 2023 | 6.7% |
| ATARA BIOTHERAPEUTICS INC | 5 | Q1 2023 | 5.6% |
View M28 Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adagio Therapeutics, Inc. | August 19, 2022 | 9,248,250 | 8.5% |
View M28 Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| SC 13G/A | 2024-02-12 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-05-25 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-10 |
View M28 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.